無料プレビュー

Revolution Medicines, Inc. (RVMD) · NASDAQ Global Select

プロフィール

Revolution Medicines is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers using proprietary small-molecule inhibitors. The company's pipeline comprises RAS(ON) Inhibitors—direct inhibitors of the active form of RAS proteins—designed as monotherapies, combination regimens with other RAS(ON) Inhibitors, or partnered with standard-of-care therapies, across pancreatic cancer, non-small cell lung cancer, and colorectal cancer indications. The company is advancing multiple clinical programs including daraxonrasib (multi-selective), zoldonrasib (

主要指標

株価: $188.12 (-6.35%)
時価総額: 400億ドル
PER（今期予想）: -19.8
PBR: 15.2
配当利回り: —
52週レンジ: $47.28 – $224.31
業種: Healthcare / Biotechnology
上場: NASDAQ Global Select
構成銘柄: —

比較会社: VRTX Vertex Pharmaceuticals Incorporated、MRNA Moderna, Inc.、REGN Regeneron Pharmaceuticals, Inc.、ARGX argenx SE、SGEN Seagen Inc.、ONC BeOne Medicines AG、ALNY Alnylam Pharmaceuticals, Inc.、ROIV Roivant Sciences Ltd.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-04 · 更新: 2026-10-09